{
  "trial_id": "NCT01500616",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "coinfection for more than 6 months before the screening visit",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "stable permissible HAART regimen for more than 8 weeks before Day 1 without switches",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "CD4 count of \u2265500 cells/mm3 and a HIV-1 and/or HIV-2 viral load \u226450,000 copies/mL at screening",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Have evidence of HCV infection genotype 1 (molecular assay)",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "ongoing clinical study of telaprevir",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Is infected or coinfected with HCV of another genotype than genotype 1",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Has a contraindication to the administration of Peg-IFN-alfa or RBV, or medical history or laboratory values that preclude treatment with Peg-IFN-alfa or RBV according to the respective local prescribing information",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Have any contraindication to the currently prescribed HAART regimen at screening",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Positive human leukocyte antigen (HLA)-B5701 genotyping result at screening (or documented result prior to screening) if abacavir is a component of HAART",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "The patient has been on IFN, RBV and direct antiviral drugs for the past 6 months. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.",
  "_meta": {
    "topic_id": "64",
    "trial_id": "NCT01500616",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}